Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Non-Current Deffered Revenue (2016 - 2024)

BioCorRx (BICX) has disclosed Non-Current Deffered Revenue for 12 consecutive years, with $4045.0 as the latest value for Q1 2024.

  • Quarterly Non-Current Deffered Revenue changed 0.0% to $4045.0 in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $4045.0 through Mar 2024, changed 0.0% year-over-year, with the annual reading at $4045.0 for FY2023, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue hit $4045.0 in Q1 2024 for BioCorRx, roughly flat from $4045.0 in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $94592.0 in Q1 2020 to a low of $4045.0 in Q4 2022.
  • Historically, Non-Current Deffered Revenue has averaged $36384.7 across 5 years, with a median of $28675.0 in 2022.
  • Biggest five-year swings in Non-Current Deffered Revenue: plummeted 89.16% in 2022 and later changed 0.0% in 2023.
  • Year by year, Non-Current Deffered Revenue stood at $72281.0 in 2020, then tumbled by 48.39% to $37301.0 in 2021, then tumbled by 89.16% to $4045.0 in 2022, then changed by 0.0% to $4045.0 in 2023, then changed by 0.0% to $4045.0 in 2024.
  • Business Quant data shows Non-Current Deffered Revenue for BICX at $4045.0 in Q1 2024, $4045.0 in Q4 2023, and $4045.0 in Q3 2023.